Yelena Janjigian

Yelena Janjigian

Medical Oncologist

Gastrointestinal Oncology

Memorial Sloan Kettering Cancer Center

USA, New York

Yelena Y. Janjigian, MD, is a Professor and Chief of the Gastrointestinal Oncology Service at Memorial Sloan Kettering Cancer Center in New York. She joined MSK’s faculty in 2009 and became chief in 2018. An expert in gastric and esophageal cancers, Dr. Janjigian led a pioneering combination of trastuzumab and pembrolizumab for HER2‑positive disease, achieving remarkable tumor responses and prompting a phase III follow‑up trial.

Present Title & Affiliation

Chief of the Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Professor of Medicine, Weill Cornell Medical College - New York, NY, USA

YearsPosition/TitleInstitution

Education & Training

Academic Degrees
1994 – 1998BS in Biological PsychologyUniversity of California, San Diego, CA, USA
1999 – 2003MDNew York University of Medicine, New York, NY, USA

Postgraduate Training
05/2003 – 08/2004Internship Internal MedicineNew York University School of Medicine/Bellevue Hospital - New York, NY, USA
08/2004 – 07/2006Residency Internal MedicineNew York University School of Medicine/Bellevue Hospital - New York, NY, USA
07/2006 – 06/2009Fellowship Hematology/OncologyMemorial Sloan Kettering Cancer Center – New York, NY, USA
07/2006 – 06/2009Fellowship Hematology/OncologyWeill Cornell Medical College – New York, NY, USA

Professional Positions & Employment

Academic Appointments
09/2023 – PresentMemberMemorial Sloan Kettering Cancer Center- New York, NY, USA
2023 – PresentProfessor of MedicineWeill Cornell Medical College - New York, NY, USA
11/2019 – 2023Associate Professor of MedicineWeill Cornell Medical College - New York, NY, USA
04/2019 – 09/2023Associate MemberMemorial Sloan Kettering Cancer Center - New York, NY, USA
07/2014 – 06/2018Adjunct FacultyRockefeller University - New York, NY, USA
02/2014 – 11/2019Assistant Professor of MedicineWeill Cornell Medical College - New York, NY, USA
12/2013 – 04/2019Assistant MemberMemorial Sloan Kettering Cancer Center - New York, NY, USA
11/2009 – 01/2014Instructor in MedicineWeill Cornell Medical College - New York, NY, USA
10/2009 – 12/2013Assistant Member (Level I)Memorial Sloan Kettering Cancer Center - New York, NY, USA

Hospital Appointments
2023 – PresentAttending Physician, GI ServiceMemorial Hospital for Cancer and Allied Disease New York- New York, NY, USA
2019 – 2023Associate Attending Physician, GI ServiceMemorial Hospital for Cancer and Allied Disease New York - New York, NY, USA
2009 – 2019Assistant Attending Physician, GI ServiceMemorial Hospital for Cancer and Allied Diseases New York - New York, NY, USA

Institutional Leadership Activities
2018-PresentChief, Gastrointestinal Oncology ServiceMemorial Sloan Kettering Cancer Center, NY, NY, USA

Institutional Administrative Activities
2020- PresentMemberWeill Cornell Graduate School Mentoring Training (WCGS)
2020-PresentCo-ChairBiospecimen Committee, MSK Integrated Diagnostics Initiative
2019-PresentMemberOversight Committee within COIC
2019-PresentPhysician LeaderConflict of Interest Committee (COIC)
2015-2018VP and PresidentMemorial Hospital Alumni Society
2017-PresentMemberStrategic Initiatives Committee-Physical Sciences into Medicine
2016ReviewerSociety of MSK Grants Program
2015-PresentMemberClinical Genomics Annotation Committee
2012- 2016Unit LeaderMSK Gastrointestinal Oncology Inpatient Unit Leader
2011-PresentLeaderBiweekly Gastrointestinal Oncology Clinical Case conference
2011-2018MemberMSK Chemotherapy Near Miss Review Group
2011-2018Vice-ChairMSK Chemotherapy Practice Committee
2010-2018MemberMSK Quality Assurance Committee Reviewer
2009 – 2018MemberGastric and Esophageal Disease Management Team
2020-PresentDMT LeadGastric and Esophageal Disease Management Team

Extramural Institutional Committee Activities
2016 – PresentMemberESMO Congress, Scientific Committee
2023- PresentChairGiants of Cancer Care Steering Committee, MJH Life Sciences
2023- PresentEditorial Board MemberOncoDaily
2024- PresentChairDebbie’s Deam Foundation Medical Advisory Board
2024- PresentEditorial Board MemberOncoDaily Medical Journal
2024- PresentCo-ChairOncoDaily Party, P53 Inc
2026Scientific Co-ChairESMO Congress

Professional Organizationas and Society Memberships
2023 – PresentAmerican Society for Clinical Investigation
2022 – PresentASCO/AACR Methods in Clinical Cancer Research Workshop
2022 – PresentSteering Committee, IDEA (Individuals with Disabilities Education Act)
2022 – PresentSteering Committee Giants of Cancer Care
2022 – PresentInternational Gastric Cancer Association Council
2021 – PresentBridge Project Review Panel
2021 – PresentUniversity of Arizona Cancer Center, NCI P50 GI Spore Advisory Board Member
2020 – 2021Peer Reviewed Cancer Research Program (PRCRP)
2016 – PresentEuropean Society of Medical Oncology Congress Scientific Committee
2015 – 2021American Society of Clinical Oncology TAPUR Study Molecular Tumor Board
2013 – PresentEuropean Society for Medical Oncology
2012 – 2021National Esophageal Cancer Task Force
2012 – 2021Alliance for Clinical Trials in Oncology – Upper GI Task Force
2010 – PresentAmerican Association of Cancer Research
2006 – PresentAmerican Society of Clinical Oncology
2014 – 2017American Society of Clinical Oncology Cancer Research Committee
2007 – 2008New York Academy of Science
2005 – 2006American College of Physicians
2000 – 2004American Medical Association

Honors & Awards
1996 – 1998Dean’s ListUniversity of California, San Diego
1998Cum LaudeUniversity of California, San Diego
1998Golden Key International Honour SocietyGolden Key Honor Society
2008 – 2009ASCO Foundation Merit AwardAmerican Society of Clinical Oncology
2009MSK Society Grant AwardMSK
2011 – 2013NIH Loan Repayment ProgramNational Institutes of Health
2012 – 2012MSK Translational and Integrative Team AwardMSK
2013ASCO Foundation Career Development AwardAmerican Society of Clinical Oncology
2014 – 2016MSK Experimental Therapeutics Grant AwardMSK
2015 – 2017Cycle for Survival Grant AwardCycle for Survival
2019DDF Tree of Life Medical AwardDebbie’s Dream Foundation
2020 – 2021Fred’s Team AwardFred’s Team
2023, 2024, 2025100 Influential Women in OncologyOncoDaily

Innovation In Gastroesophageal Cancer

Selected Publications

Peer-reviewed Research Articles  

  1. Janjigian YY, McDonnell K, Kris MG, Shen R, Sima CS, Bach PB, Rizvi NA, Riely GJ. Pack-years of cigarette smoking as a prognostic factor in patients with stage IIIB/IV nonsmall cell lung cancer. Cancer 2010; Feb 1; 116:670-675. PMCID:PMC2815173
  2. Janjigian YY, Lee W, Kris MG, Miller VA, Krug LM, Azzoli CG, Senturk E, Calcutt MW, Rizvi NA. A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors. Cancer Chemother Pharmacol 2010; Apr; 65:833-8. PMID:19672598, NIHMS324552
  3. De Braganca KC, Janjigian YY, Azzoli Cg, Kris MG, Pietanza MC, Noaln CP, Omuro AM, Holodny AI, Lassman AB. Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer. J Neurooncol. 2010 Dec; 100(3):443-7. PMCID: 3246379
  4. Janjigian YY, Park BJ, Zakowski MF, Ladanyi M, Pao W, D’Angelo SP, Kris MG, Shen R, Zheng J, Azzoli CG. Impact on disease free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor Epidermal Growth Factor Receptor (EGFR) mutations. J Thorac Oncol 2011 Mar; 6(3):569-75.PMID:21150674
  5. Janjigian YY, Azzoli CG, Krug LM, Pereira LK, Rizvi NA, Pietanza MC, Kris MG, Ginsberg MS, Pao W, Miller VA, Riely GJ. Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib. Clin Cancer Res 2011 Apr 15;17(8):2521-7. PMID:21248303
  6. Janjigian YY, Tang LH, Coit DG, Kelsen DP, Francone TD, Weiser MR, Jhanwar SC, Shah MA. MET expression and amplification in patients with localized gastric cancer. Cancer Epidemiol Biomarkers Prev (Cover Article). 2011 May; 20(5):1021-7. PMID:21393565
  7. Shah MA, Khanin R, Tang L, Janjigian YY, Klimstra DS, Gerdes H, Kelsen DP. Molecular classification of gastric cancer: a new paradigm. Clin Cancer Res. 2011 May 1;17(9):2693- 701.PMCID: 3100216
  8. Oxnard GR, Janjigian YY, Arcila ME, Sima CS, Kass SL, Riely GJ, Pao W, Kris MG, Ladanyi M, Azzoli CG, Miller VA. Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib. Clin Cancer Res. 2011 Oct 1;17(19):6322-8 PMCID:3186869
  9. Lowery MA, Kelsen DP, Stadler ZK, Yu KH, Janjigian YY, Ludwig E, D’Adamo DR, Salo-Mullen E, Robson ME, Allen PJ, Kurtz RC, O’Reilly EM. An Emerging Entity: Pancreatic Adenocarcinoma Associated with a Known BRCA Mutation: Clinical Descriptors, Treatment Implications, and Future Directions. Oncologist. 2011;16(10):1397-402 PMCID:3228075
  10. Tafe LJ, Janjigian YY, Zaidinski M, Hedvat CV, Hameed MR, Tang LH, Hicks JB, Shah MA, Barbashina V. HER2 testing in gastric cancer: correlation between IHC and FISH. Arch Pathol Lab Med. 2011 Nov; 135(11):1460-5. PMID:22032573
  11. Smyth EC, Capanu M, Janjigian YY, Kelsen DK, Coit D, Strong VE, Shah MA. Tobacco Use Is Associated with Increased Recurrence and Death from Gastric Cancer. Ann Surg Oncol. 2012 Jul; 19(7):2088-94. PMID:22395977
  12. Janjigian YY, Werner D, Pauligk C, Steinmetz K, Kelsen DP, Jäger E, Altmannsberger HM, Robinson E, Tafe LJ, Tang LH, Shah MA, Al-Batran SE. Prognosis of Metastatic Gastric Cancer by HER2 Status: A European and US International Collaborative Analysis.” Ann Oncol. 2012 Oct;23(10):2656-62. PMID:22689179
  13. Takezawa K, Pirazzoli V, Arcila ME, Nebhan CA, Song X, de Stanchina E, Ohashi K, Janjigian YY, Spitzler PJ, Melnick MA, Riely GJ, Kris MG, Miller VA, Ladanyi M, Politi K, Pao W. HER2 levels affect sensitivity and resistance to EGFR inhibition in EGFR mutant lung cancer. Cancer Discov. 2012 Oct; 2(10):922-33. PMID:22956644
  14. D’Angelo SP, Janjigian YY, Ahye N, Riely GJ, Chaft JE, Sima CS, Shen R, Zheng J, Dycoco J, Kris MG, Zakowski MF, Ladanyi M, Rusch V, Azzoli CG. Distinct clinical course of EGFR- mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib. J Thorac Oncol. 2012 Dec; 7(12):1815-22. PMID:23154553
  15. Janjigian YY, Ku GY, Campbell JC, Shah MA, Capanu M, Kelsen DP, Ilson DH. Phase II trial of cetuximab plus cisplatin and irinotecan in patients with cisplatin and irinotecan-refractory metastatic esophagogastric cancer. Am J Clin Oncol. 2014 Apr;37(2):126-30. PMID:23211227
  16. Janjigian YY, Villegas NV, Holland JP, Divilov V, Carlin SD, Gomes Da Gama EM, Chiosis G, Carbonetti G, de Stanchina E, Lewis JS. Monitoring Afatinib Treatment in HER2 Positive Gastric  Cancer with 18-F-FDG and 89-Zr-trastuzumab PET. J Nucl Med. 2013 Jun;54(6):936-43. PMID: 23578997
  17. Lee KS, Hwang S, Hurtado Rua SM, Janjigian YY, Gollub MJ. Distinguishing Benign and Life- Threatening Pneumatosis Intestinalis in Patients with Cancer by CT Imaging Features. AJR Am J Roentgenol. 2013 May;200(5):1042-7 PMID: 23617487
  18. Epstein AS, Volandes AE, Chen LY, Gary KA, Li Y, Agre P, Levin TT, Reidy DL, Meng RD, Segal NH, Yu KH, Abou-Alfa GK, Janjigian YY, Kelsen DP, O’Reilly EM. A randomized controlled trial of a cardiopulmonary resuscitation video in advance care planning for progressive pancreas and hepatobiliary cancer patients. J Palliat Med. 2013 Jun;16(6):623-31 PMID:  23725233
  19. Gerber N, Ilson DH, Wu AJ, Janjigian YY, Kelsen DP, Zheng J, Zhang Z, Bains MS, Rizk N, Rusch VW, Goodman KA. Outcomes of induction chemotherapy followed by chemoradiation using  intensity-modulated radiation therapy for esophageal adenocarcinoma. Dis Esophagus. 2014 Apr;27(3):235-41.PMID: 23796070
  20. Hudis C, Swanton C, Janjigian YY, Lee R, Sutherland SC, Chandarlapaty S, Lehman R, Hamilton R, Knowles J, Yan L, Sullivan D, Hudis C. A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors. Breast Cancer Res. 2013 Nov 19; 15(6):R110. PMID: 24252402
  21. Park DJ, Yoon C, Thomas N, Ku GY, Janjigian YY, Kelsen DP, Ilson DH, Goodman KA, Tang LH, Strong VE, Coit DG, Yoon SS. Prognostic significance of targetable angiogenic and growth factors in patients undergoing resection for gastric and gastroesophageal junction cancers. Ann Surg Oncol. 2014 Apr;21(4):1130-7. PMID: 24370903
  22. Yoon C, Park DJ, Schmidt B, Thomas NJ, Lee HJ, Kim TS, Janjigian YY, Cohen D, Yoon SS. CD44 expression denotes a subpopulation of gastric cancer cells in which Hedgehog signalling promotes chemotherapy resistance. Clin Cancer Res. 2014 Aug 1;20(15):3974-88 PMID: 24947926
  23. Janjigian YY, Smith EF, Groen, HJM, Horn L, Gettinger S, Camidge DR, Riely GJ, Wang B, Fu Y, Chand VK, Miller VA, Pao W. Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor-Resistant EGFR-Mutant Lung Cancer with and without T790M Mutations. Cancer Discov. 2014 Sep;4(9):1036-45. PMID: 25074459
  24. Afaneh C, Abelson J, Schattner M, Janjigian YY, Ilson D, Yoon SS, Strong VE. Esophageal Reinforcement with an Extracellular Scaffold During Total Gastrectomy for Gastric Cancer. Ann Surg Oncol. 2015 Apr;22(4):1252-7. PMID: 25319574
  25. Selby LV, Vertosick EA, Sjoberg DD, Schattner MA, Janjigian YY, Brennan MF, Coit DG, Strong VE. Morbidity after Total Gastrectomy: Analysis of 238 Patients. J Am Coll Surg. 2015 May; 220(5):863-871.e2.  PMID: 25842172
  26. Janjigian YY, Vakiani E, Ku GY, Herrera JM, Tang LH, Bouvier N, Viale A, Socci ND, Capanu M, Berger M, Ilson DH. Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer PLoS One. 2015 Aug 14;10(8):e0134731. PMID: 26275293
  27. Shah MA, Janjigian YY, Stoller RG, Shibata S, Kemeny M, Ritch PS , Krishnamurthi SS, Su YB, Capanu M, Kelsen DP.A Random Assignment, Multicenter Phase II study of modified Docetaxel, Cisplatin, and Fluorouracil (DCF) versus DCF plus growth factor support in patients with metastatic gastric adenocarcinoma: A Study of the US Gastric Cancer Consortium. J Clin Oncol. 2015 Nov 20;33(33):3874-9. PMID: 26438119
  28. Chhabra A, Ong LT, Kuk D, Ku G, Ilson D, Janjigian YY, Wu A, Schöder H, Goodman KA. Prognostic significance of PET assessment of metabolic response to therapy in oesophageal squamous cell carcinoma. Br J Cancer. 2015 Dec 22;113(12):1658-65.. PMID: 26657654
  29. Nguyen A, Loo JM, Mital R, Weinberg EM, Man FY, Zeng Z, Paty PB, Saltz L, Janjigian YY, de Stanchina E, Tavazoie SF. PKLR promotes colorectal cancer liver colonization through induction of glutathione synthesis. J Clin Invest. 2016 Feb;126(2):681-94. PMID: 26784545
  30. Cao L, Selby LV, Hu X, Zhang Y, Janjigian YY, Tang L, Coit DG, Brennan MF, Strong VE. Risk factors for recurrence in T1-2N0 gastric cancer in the United States and China. J Clin Invest. 2016 Feb;126(2):681-94. PMID: 27040753
  31. Ku, GY, Kriplani A, Janjigian YY, Kelsen DP, Rusch VW, Bains M, Chou J, Capanu M, Wu AJ, Goodman KA, Ilson DH. Change in chemotherapy during concurrent radiation followed by surgery after a suboptimal positron emission tomography response to induction chemotherapy improves outcomes for locally advanced esophageal adenocarcinoma. Cancer. 2016 Jul 1;122(13):2083-90. PMID: 27152857
  32. Won E, Shah MA, Schöder H, Strong VE, Coit DG, Brennan MF, Kelsen DP, Janjigian YY, Tang LH, Capanu M, Rizk NP, Allen PJ, Bains MS, Ilson DH. Use of positron emission tomography scan response to guide treatment change for locally advanced gastric cancer: the Memorial Sloan Kettering Cancer Center experience. J Gastrointest Oncol. 2016 Aug;7(4):506-14. PMID: 27563439
  33. Strong VE, Gholami S, Shah MA, Tang LH, Janjigian YY, Schattner M, Selby LV, Yoon SS, Salo- Mullen E, Stadler ZK, Kelsen D, Brennan MF, Coit DG. Total Gastrectomy for Hereditary Diffuse Gastric Cancer at a Single Center: Postsurgical Outcomes in 41 Patients. Ann Surg. 2016 Oct 17;266(6):1006-1012. PMID: 27759617
  34. Ku GY, Bains MS, Park DJ, Janjigian YY, Rusch VW, Rizk NP, Yoon SS, Millang B, Capanu M, Goodman KA, Ilson DH. Phase II study of bevacizumab and preoperative chemoradiation for esophageal adenocarcinoma. J Gastrointest Oncol. 2016 Dec;7(6):828-837. PMID: 28078107
  35. Ross DS, Zehir A, Cheng DT, Benayed R, Nafa K, Hechtman JF, Janjigian YY, Weigelt B, Razavi P, Hyman DM, Baselga J, Berger MF, Ladanyi M, Arcila ME. Next-Generation Assessment of ERBB2 (Human Epidermal Growth Factor Receptor 2) Amplification Status: Clinical Validation in the Context of a Hybrid Capture-Based, Comprehensive Solid Tumor Genomic Profiling Assay. J Mol Diagn. 2017 Mar;19(2):244-254. PMID: 28027945
  36. Price EW, Carnazza KE, Carlin SD, Cho A, Edwards KJ, Sevak KK, Glaser JM, de Stanchina E, Janjigian YY, Lewis JS. 89-Zr-DFO-AMG102 Immuno-PET to Determine Local HGF Protein Levels in Tumors for Enhanced Patient Selection. J Nucl Med. 2017 Sep;58(9):1386-1394. PMID: 28280216
  37. Lopez-Albaitero A, Xu H, Guo H, Wang L, Wu Z, Tran H, Chandarlapaty, Scaltriti M, Janjigian YY, de Stanchina E, Cheung NV. Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody. Oncoimmunology. 2017 Mar 10;6(3):e1267891. PMID. 28405494
  38. Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, Srinivasan P, Gao J, Chakravarty D, Devlin SM, Hellmann MD, Barron DA, Schram AM, Hameed M, Dogan S, Ross DS, Hechtman JF, DeLair DF, Yao J, Mandelker DL, Cheng DT, Chandramohan R, Mohanty AS, Ptashkin RN, Jayakumaran G1, Prasad M1, Syed MH1, Rema AB1, Liu ZY1, Nafa K1, Borsu L1, Sadowska J, Casanova J, Bacares R, Kiecka IJ, Razumova A, Son JB, Stewart L, Baldi T, Mullaney KA, Al- Ahmadie H, Vakiani E, Abeshouse AA, Penson AV, Jonsson P, Camacho N, Chang MT, on HH1, Gross BE, Kundra R, Heins ZJ, Chen HW, Phillips S, Zhang H, Wang J, Ochoa A, Wills J, Eubank M, Thomas SB, Gardos SM, Reales DN, Galle J, Durany R, Cambria R, Abida W, Cercek A, Feldman DR, Gounder MM, Hakimi AA, Harding JJ, Iyer G, Janjigian YY, Jordan EJ, Kelly CM, Lowery MA, Morris LGT, Omuro AM, Raj N, Razavi P, Shoushtari AN, Shukla N, Soumerai TE, Varghese AM, Yaeger R, Coleman J, Bochner B, Riely GJ, Saltz LB, Scher HI, Sabbatini PJ, Robson ME, Klimstra DS, Taylor BS Baselga J Schultz N Hyman DM, Arcila ME, Solit DB, Ladanyi M1, Berger MF. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017 Jun;23(6):703-713. PMID: 28481359
  39. O’Donoghue JA, Lewis JS, Pandit-Taskar N, Fleming SE, Schoder H, Larson SM, Beylergil V1, Ruan S, Lyashchenko S, Zanzonico PB, Weber WA, Carrasquillo JA, Janjigian YY. Pharmacokinetics, biodistribution, and radiation dosimetry for 89Zr-trastuzumab in patients with esophagogastric cancer. J Nucl Med. 2017 Jun 21;59(1):161-166. PMID: 28637800
  40. Chakravarty D, Gao J, Phillips SM, Kundra R, Zhang H, Wang J, Rudolph JE, Yaeger R, Soumerai T, Nissan MH, Chang MT, Chandarlapaty S, Traina TA, Paik PK, Ho AL, Hantash FM, Grupe A, Baxi SS, Callahan MK, Snyder A, Chi P, Danila D, Gounder M, Harding JJ, Hellmann MD, Iyer G, Janjigian YY, Kaley T, Levine DA, Lowery M, Omuro A, Postow MA, Rathkopf D, Shoushtari AN, Shukla N, Voss M, Paraiso E, Zehir A, Berger MF, Taylor BS, Saltz LB, Riely GJ, Ladanyi M, Hyman DM, Baselga J, Sabbatini P, Solit DB, Schultz N. OncoKB: A Precision Oncology Knowledge Base. JCO Precis Oncol 2017 July Jul;2017:PO.17.00011. doi: 10.1200/PO.17.00011. Epub 2017 May 16. PMID: 28890946
  41. Hernandez JM1, Beylergil V, Goldman DA, van Beek E, Gonen M, Tang L, Downey R, Rizk N, Shah M, Strong V, Janjigian YY, Schöder H, Coit DG. Post-Treatment/Pre-operative PET Response Is Not an Independent Predictor of Outcomes for Patients With Gastric and GEJ Adenocarcinoma. Ann Surg. 2017 Aug 1;267(5):898-904 MID: 28767564
  42. Horn L, Gettinger S, Camidge DR, Smit EF, Janjigian YY, Miller VA, Pao W, Freiwald M, Fan J, Wang B, Chand VK, Groen HJM.. Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib. Lung Cancer 2017 Nov; 113:51-58. PMID: 29110849
  43. Schram AM, Reales D, Galle J, Cambria R, Durany R, Feldman D, Sherman E, Rosenberg J, D’Andrea G, Baxi S, Janjigian YY, Tap W, Dickler M, Baselga J, Taylor BS, Chakravarty D, Gao J, Schultz N, Solit DB, Berger MF, Hyman DM. Oncologist use and perception of large panel next-generation tumour sequencing. Ann Oncol. 2017 Sep 1;28(9):2298-2304. PMID: 28911072.
  44. Jordan EJ, Lowery MA, Basturk O, Allen PJ, Yu KH, Tabar V, Beal K, Reidy DL, Yamada Y, Janjigian YY, Abou-Alfa GK, O’Reilly EM. Brain Metastases in Pancreatic Ductal Adenocarcinoma: Assessment of Molecular Genotype-Phenotype Features-An Entity With an Increasing Incidence? Clin Colorectal Cancer. 2018;17(2):e315-e321. PMID: 29496399
  45. Barbetta A, Hsu M, Tan KS, Stefanova D, Herman K, Adusumilli PS, Bains MS, Bott MJ, Isbell JM, Janjigian YY, Ku GY, Park BJ, Wu AJ, Jones DR, Molena D. Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery for stage II to III esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg. 2018 Jun; 55(6):2710-2721.e3. PMID: 29548582
  46. van Beek EJAH, Hernandez JM, Goldman DA, Davis JL, McLoughlin K, Ripley RT, Kim TS, Tang LH, Hechtman JF, Zheng J, Capanu M, Schultz N, Hyman DM, Ladanyi M, Berger MF, Solit DB, Janjigian YY, Strong VE. Rates of TP53 Mutation are Significantly Elevated in African American Patients with Gastric Cancer. Ann Surg Oncol. 2018 Jul;25(7):2027-2033. PMID: 31898094
  47. Barbetta A, Nobel TB, Sihag S, Hsu M, Tan KS, Bains MS, Isbell JM, Janjigian YY, Wu AJ, Bott MJ, Jones DR, Molena D. Neutrophil to Lymphocyte Ratio as Predictor of Treatment Response in Esophageal Squamous Cell Cancer. Ann Thorac Surg. 2018 May 5;106(3):864-871. PMID: 29738752
  48. Janjigian YY, Sanchez-Vega F, Jonsson P, Chatila W, Hechtman J, Ku G, Riches J, Tuvy Y, Kundra R, Bouvier N, Vakiani E, Gao J, Heins Z, Gross B, Kelsen D, Zhang L, Strong V, Schattner M, Gerdes H, Coit D, Bains M, Satdler Z, Rusch V, Jones D, Molena D, Shia J, Robson M, Capanu M, Middha S, Zehir A, Hyman D, Scaltriti M, Ladanyi M, Rosen N, Ilson D, Berge M,  Tang L, Taylor B, Solit D, Schultz N. Genetic predictors of response to systemic therapy in esophagogastric cancer. Cancer Discov. 2018 Jan;8(1):49-58. PMID: 29122777
  49. Strong VE, Gholami S, Shah MA, Tang LH, Janjigian YY, Schattner M, Selby LV, Yoon SS, Salo-Mullen E, Stadler ZK, Kelsen D, Brennan MF, Coit DG. Total Gastrectomy for Hereditary Diffuse Gastric Cancer at a Single Center: Postsurgical Outcomes in 41 Patients. Ann Surg. 2017 Dec;266(6):1006-1012. PMID: 27759617
  50. Fan PD, Narzisi G, Jayaprakash AD, Venturini E, Robine N, Smibert P, Germer S, Yu HA, Jordan EJ, Paik PK, Janjigian YY, Chaft JE, Wang L, Jungbluth AA, Middha S, Spraggon L, Qiao H, Lovly CM, Kris MG, Riely GJ, Politi K, Varmus H, Ladanyi M.  YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics. Proc Natl Acad Sci USA. 2018 June 26;115(26):E6030-6038. PMID: 29875142
  51. Mondaca S, Margolis M, Sanchez-Vega F, Jonssson P, Riches JC, Ku GY, Hechtman JF, Tuvy Y, Berger MF, Shah MA, Kelsen DK, Ilson DH, Yu K, Goldberg Z, Epstein A, Desai A, Chung V, Chou JF, Capanu M, Solit DB, Schultz N, Janjigian YY. Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer. Gastric Cancer 2018 August 7;22(2):355-362 PMID: 30088161
  52. Janjigian YY, Bendell J, Calvo E, Kim J,. Ascierto P, Sharma P, Ott P, Peltola K, Jaeger D,  Evans T, DeBraud, F, Chau I, Tschaika M, Harbison C, Dorange C, Le D. CheckMate 032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients with Metastatic Esophagogastric Cancer. J Clin Oncol. 2018 October 1;36(28):2836-2844. PMID: 30110194
  53. Harding JJ, Nandakumar S, Armenia J, Khalil DN, Albano M, Ly M, Shia J, Hechtman JF, Kundra R, El Dika I, Do RK, Sun Y, Kingham TP, D’Angelica MI, Berger MF, Hyman DM, Jarnagin WR, Klimstra DS, Janjigian YY, Solit DB, Schultz N, Abou-Alfa GK. Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next Generation Sequencing for Matching Patients to Targeted and Immune Therapies. Clin Cancer Res. 2018 October 29;25(7):2116-2126. PMID: 30373752
  54. Harding JJ, Lowery MA, Shih AH, Schvartzman JM, Hou S, Famulare C, Patel M, Roshal M, Do RK, Zehir A, You D, Selcuklu SD, Viale A, Tallman MS, Hyman DM, Reznik E, Finley LWS, Papaemmanuil E, Tosolini A, Frattini MG, MacBeth KJ, Liu G, Fan B, Choe S, Wu B, Janjigian YY, Mellinghoff IK, Diaz LA, Levine RL, Abou-Alfa GK, Stein EM, Intlekofer AM. Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition. Cancer Discovery. 2018 Dec;8(12):1540-1547 PMID: 30355724
  55. Latham A, Srinivasan P, Kemel Y, Shia J, Bandlamudi C, Mandelker D, Middha S, Hechtman J, Zehir A, Dubard-Gault M, Tran C, Stewart C, Sheehan M, Penson A, DeLair D, Yaeger R, Vijai J, Mukherjee S, Galle J, Dickson MA, Janjigian YY, O’Reilly EM, Segal N, Saltz LB, Reidy-Lagunes D, Varghese AM, Bajorin D, Carlo MI, Cadoo K, Walsh MF, Weiser M, Aguilar JG, Klimstra DS, Diaz LA Jr, Baselga J, Zhang L, Ladanyi M, Hyman DM, Solit DB, Robson ME, Taylor BS, Offit K, Berger MF, Stadler ZK. Microsatellite Instability Is Associated with the Presence of Lynch Syndrome Pan-Cancer. J Clin Oncol. 2018 October 30;37(4)286-295. PMID: 30376427
  56. Greally M, Chou J, Molena D, Rusch VW, Bains MS, Park BJ, Wu AJ, Goodman KA, Kelsen DP, Janjigian YY, Ilson DH, Ku GY. PET scan-directed chemoradiation for esophageal squamous cell carcinoma: no benefit for a chance in chemotherapy in PET non-responders. J Thorac Oncol. 2018 November 1;14(3):540-546. PMID: 30391577
  57. Sanchez-Vega F, Hechtman J, Castel P, Ku GY, Tuvy Y, Imtiaz T, Bouvier N, Soon J, Vakiani E, Schattner M, Kelsen D, Lefkowitz R, Brown K, Lacouture M, Capanu M,. Berger M, Lacobuzio-Donahue C, Ilson D, De Stanchina E, Lewis J, Carrasquillo J, Taylor B,. Solit D., Schultz N, Scaltriti M, Janjigian YY. EGFR and MET determine outcome in ERBB2 esophagogastric cancer. Cancer Discov. 2018 November 21;9(2):199-209. PMID: 30463996
  58. Pereira PMR, Sharma SK, Carter LM, Edwards KJ, Pourat J, Ragupathi A, Janjigian YY, Durack JC, Lewis JS. Caveolin-1 mediates cellular distribution of HER2 and affects trastuzumab binding and therapeutic efficacy. Nat Commun. 2018 December 3;9(1):5137. PMID: 30510281
  59. Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, Barron DA, Zehir A, Jordan EJ, Omuro A, Kaley TJ, Kendall SM, Motzer RJ, Hakimi AA, Voss MH, Russo P, Rosenberg J, Iyer G, Bochner BH, Bajorin DF, Al-Ahmadie HA, Chaft JE, Rudin CM, Riely GJ, Baxi S, Ho AL, Wong RJ, Pfister DG, Wolchok JD, Barker CA, Gutin PH, Brennan CW, Tabar V, Mellinghoff IK, DeAngelis LM, Ariyan CE, Lee N, Tap WD, Gounder MM, D’Angelo SP, Saltz L, Stadler ZK, Scher HI, Baselga J, Razavi P, Klebanoff CA, Yaeger R, Segal NH, Ku GY, DeMatteo RP, Ladanyi M, Rizvi NA, Berger MF, Riaz N, Solit DB, Chan TA, Morris LGT. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019 January 14; 51 202-206. https://doi.org/10.1038/s41588-018-0312-8
  60. Nobel TB, Livschitz J, Eljalby M, Janjigian YY, Bains MS, Adusumilli PS, Jones DR, Molena D. Unique Considerations for Females Undergoing Esophagectomy. Annals of Surgery. 2019 January 17;272(1):113-117. PMID: 30672802
  61. Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, Barron DA, Zehir A, Jordan EJ, Omuro A, Kaley TJ, Kendall SM, Motzer RJ, AriHakimi A, Voss MH, Russo P, Rosenberg J, Iyer G, Bochner BH, Bajorin D, Al-Ahmadie HA, Chaft JE, Rudin CM, Riely GJ, Baxi S, Ho AL, Wong RJ, Pfister DG, Wolchok JD, Barker CA, Gutin PH, Brennan CW, Tabar V, Mellinghoff IK, DeAngelis LM, Ariyan CE, Lee N, Tap WD, Grounder MM, D’Angelo SP, Saltz L, Stadler ZK, Scher HI, Baslega J, Razavi P, Klebanoff CA, Yaeger R, Segal NH, Ku GY, DeMatteo RP, Ladanyi M, Rizvi N, Berger MF, Riaz N, Solid DB, Chan TA, Morris LGT. Tumor Mutational Load Predicts Survival After Immunotherapy Across Multiple Cancer Types. Nat Gen. 2019 February 1;51(2):202-206. PMID: 30643254
  62. Latham A, Srinivasan P, Kemel Y, Shia J, Bandlamudi C, Mandelker D, Middha S, Hechtman J, Zehir A, Dubard-Gault M, Tran C, Stewart C, Sheehan M, Penson A, DeLair D, Yaeger R, Vijai J, Mukherjee S, Galle J, Dickson MA, Janjigian YY, O’Reilly EM, Segal N, Saltz LB, Reidy-Lagunes D, Varghese AM, Bajorin D, Carlo MI, Cadoo K, Walsh MF, Weiser M, Aguilar JG, Klimstra DS, Diaz LA Jr, Baselga J, Zhang L, Ladanyi M, Hyman DM, Solit DB, Robson ME, Taylor BS, Offit K, Berger MF, Stadler ZK.Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. Clin Oncol. 2019 February 9.;37(4):286-295. MID: 30376427
  63. Sanchez-Vega F, Hechtman JF, Castel P, Ku GY, Tuvy Y, Won H, Fong CJ, Bouvier N, Nanjangud GJ, Soong J, Vakiani E, Schattner M, Kelsen DP, Lefkowitz RA, Brown K, Lacouture ME, Capanu M, Mattar M, Qeriqi B, Cecchi F, Tian Y, Hembrough T, Nagy RJ, Lanman RB, Larson SM, Pandit-Taskar N, Schöder H, Iacobuzio-Donahue CA, Ilson DH, Weber WA, Berger MF, de Stanchina E, Taylor BS, Lewis JS, Solit DB, Carrasquillo JA, Scaltriti M, Schultz N, Janjigian YY. EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer. Cancer Discov. 2019 February;9(2):199-209. PMID: 30463996
  64. Greally M, Chou JF, Molena D, Rusch VW, Bains MS, Park BJ, Wu AJ, Goodman KA, Kelsen DP, Janjigian YY, Ilson DH, Ku GY.Positron-Emission Tomography Scan-Directed Chemoradiation for esophageal Squamous Cell Carcinoma: No Benefit for a Change in Chemotherapy in Positron-Emission Tomography Nonresponders. Thorac Oncol. 2019 March 14;14(3):530-546. PMID: 30391577
  65. Mondaca S, Margolis M, Sanchez-Vega F, Jonsson P, Riches JC, Ku GY, Hechtman JF, Tuvy Y, Berger MF, Shah MA, Kelsen DP, Ilson DH, Yu K, Goldberg Z, Epstein AS, Desai A, Chung V, Chou JF, Capanu M, Solit DB, Schultz N, Janjigian YY. Phase II Study of Trastuzumab with Modified Docetaxel, Cisplatin, and 5 Fluorouracil in Metastatic HER2-Positive Gastric Cancer. Gastric Cancer. 2019 Mar;22(2):355-362. PMID: 30480560
  66. Won E, Basunia A, Chatila WK, Hechtman JF, Chou JF, Ku GY, Chalasani SB, Boyar MS, Goldberg Z, Desai AM, Tuvy Y, Berger MF, Tang LH, Kelsen DP, Schattner M, Ilson DH, Capanu M, Solit DB, Schultz N, Janjigian YY. Efficacy of Combined VEGFR1-3, PDGFα/β, and FGFR1-3 blockade Using Nintedanib for Esophagogastric Cancer. Clin Cancer Res. 2019 April 5; 25(13):3811-3817. PMID: 30952642
  67. Pereira PM, Mandleywala K, Ragupathi A, Carter LM, Goos JAACM, Janjigian YY, Lewis JS. Temporal Modulation of HER2 Membrane Availibility Increases Pertuzumab Uptake and Pretargeted Molecular Imaging of Gastric Tumors. J Nucl Med. 2019 June 6;60(11):1569-1578. PMID: 31171598
  68. Greally M, Chou JF, Chatila WK, Margolis M, Capanu M, Hechtman JF, Tuvy Y, Kundra R, Daian F, Ladanyi M, Kelsen DP, Ilson DH, Berger MF, Tang LH, Solit DB, Diaz LA, Schultz N, Janjigian YY, Ku GY. Clinical and molecular predictors of response to immune checkpoint inhibitors in patients with advanced esophagogastric cancer. Clin Cancer Res. 2019 Jul 23;25(20):6160-6169. PMID: 31337644
  69. Moy RH, Dos Santos Fernandes G, Jonsson P, Chou JF, Basunia A, Ku GY, Chalasani SB, Boyar MS, Goldberg Z, Desai AM, Gabler A, Berger MF, Tang LH, Hechtman JF, Kelsen DP, Schattner M, Ilson DH, Solit DB, Taylor BS, Schultz N, Capanu M, Janjigian YY. Regorafenib in Combination with First-Line Chemotherapy for Metastatic Esophagogastric Cancer Oncologist. 2020 Jan;25(1):e68-e74. pii: theoncologist.2019-0492. PMID: 31570517
  70. Nobel T, Dave N, Eljalby M, Xing X, Barbetta A, Hsu M, Tan KS, Janjigian YY, Bains M, Sihag S, Jones D, Molena D. Ann. Incidence and Risk Factors for Isolated Esophageal Cancer Recurrence to the Brain. Thorac Surg. 2019 Oct 12. pii: S0003-4975(19)31583-8. PMID: 31614136
  71. J. Datta, E. M. Da Silva, C. Kandoth, T. Song, A. E. Russo, J. M. Hernandez, B. S. Taylor, Janjigian YY, L. H. Tang, D. B. Solit and V. E. Strong. Poor survival after resection of early gastric cancer: extremes of survivorship analysis reveal distinct genomic profile. British Journal of Surgery. 2019 Nov;107(1):14-19. PMID: 31763684
  72. Yamaguchi N, Weinberg EM, Nguyen A, Liberti MV, Goodarzi H, Janjigian YY, Paty PB, Saltz LB, Kingham TP, Loo JM, de Stanchina E, Tavazoie SF. PCK1 and DHODH drive colorectal cancer liver metastatic colonization and hypoxic growth by promoting nucleotide synthesis. Elife. 2019 Dec 16;8:e52135. doi: 10.7554/eLife.52135. PMID: 31841108
  73. Janjigian YY, Maron S. B., Chatila W. K., Millang B., Chavan S. S., Alterman C., Chou J. F., Segal M. F., Simmons M. Z., Momtaz P., Shcherba M., Ku G. Y., Zervoudakis A., Won E. S., Kelsen D. P., Ilson D. H., Nagy R. J., Lanman R. B., Ptashkin R. N., … Hechtman J. F. 2020. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal Junction cancer: An open-label, single-arm, phase 2 trial. The Lancet Oncology. 2020 Jun;21(6)821-831. PMID: 32437664
  74. Yan P, Patel HJ, Sharma S, Corben A, Wang T, Panchal P, Yang C, Sun W, Araujo TL, Rodina A, Joshi S, Robzyk K, Gandu S, White JR, de Stanchina E, Modi S, Janjigian YY, Hill EG, Liu B, Erdjument-Bromage H, Neubert TA, Que NLS, Li Z, Gewirth DT, Taldone T, Chiosis G. Molecular Stressors Engender Protein Connectivity Dysfunction through Abberrant N-Glycosylation of a Chaperone. Cell Rep. 2020 Jun 30;31(13):107840 PMID: 32610141
  75. Jee J, Foote MB, Lumish M, Stonestrom AJ, Wills B, Narendra V, Avutu V, Murciano-Goroff YR, Chan JE, Derkach A, Philip J, Belenkaya R, Kerpelev M, Maloy M, Watson A, Fong C, Janjigian YY, Diaz LA Jr, Bolton KL, Pessin MS. Chemoterapy and COVID-19 Outcomes in Patients with Cancer. Clin Oncol. 2020 Oct 20;38(30):3538-3546. JCO2001307. PMID: 32795225
  76. Vos EL, Salo-Mullen EE, Tang LH, Schattner M, Yoon SS, Gerdes H, Markowitz AJ, Mandelker D, Janjigian YY, Offitt K, Coit DG, Stadler ZK, Strong VE. Indications for Total Gastrectomy in CDH1 Mutation Carriers and Outcomes of Risk-Reducing Minimally Invasive and Open Gastrectomies. JAMA Surg. 2020 Nov 1;155(11):1050-1057. PMID: 32997132
  77. Sihag S, Nobel T, Hsu M, Tan KS, Carr R, Janjigian YY, Tang LH, Wu AJ, Bott MJ, Isbell JM, Bains MS, Jones DR, Molena D. A More Extensive Lymphadenectomy Enhances Survival Following Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Adenocarcinoma. Ann Surg. 2020 Nov 12;276(2):312-317. PMID: 33201124
  78. Sihag S, Nobel T, Hsu M, Torre S, Tan KS, Janjigian YY, Ku GY, Tang LH, Wu AJ, Maron SB, Bains MS, Jones DR, Molena D. Survival Following Trimodality Therapy in Patients With Locally Advanced Esophagogastric Adenocarcinoma: Does Only a Complete Pathologic Response Matter? Ann Surg. 2020 Nov 17;276(6):1017-1022. PMID: 33214465
  79. Sihag S, Ku GY, Tan KS, Nussenzweig S, Wu A, Janjigian YY, Jones DR, Molena D. Safety and feasibility of esophagectomy following combined immunotherapy and chemoradiotherapy for esophageal cancer. J Thorac Cardiovasc Surg. 2020 Dec 17;161(3):836-843. doi: S0022-5223(20)33192-5. PMID: 33485662.
  80. Varghese AM, Patel J, Janjigian YY, Meng F, Selcuklu SD, Iyer G, Houck-Loomis B, Harding JJ, O’Reilly EM, Abou-Alfa GK, Lowery MA, Berger MF. Noninvasive Detection of Polyclonal Acquired Resistance to FGFR Inhibition in Patients With Cholangiocarcinoma Harboring FGFR2 Alterations. JCO Precis Oncol. 2021 Jan 8;5:PO.20.00178. doi: 10.1200/PO.20.00178. PMID: 34250419.
  81. Nakauchi M, Vos E, Tang LH, Gonen M, Janjigian YY, Ku GY, Ilson DH, Maron SB, Yoon SS, Brennan MF, Coit DG, Strong VE. Outcomes of Neoadjuvant Chemotherapy for Clinical Stages 2 and 3 Gastric Cancer Patients: Analysis of Timing and Site of Recurrence. Ann Surg Oncol. 2021 Feb 10;28(9):4829-4838. doi: 10.1245/s10434-021-09624-5. PMID: 33566242.
  82. Nakauchi M, Vos E, Janjigian YY, Ku GY, Schattner MA, Nishimura M, Gonen M, Coit DG, Strong VE. Comparison of Long- and Short-term Outcomes in 845 Open and Minimally Invasive Gastrectomies for Gastric Cancer in the United States. Ann Surg Oncol. 2021 Mar 11;28(7):3532-3544 doi: 10.1245/s10434-021-09798-y. PMID: 33709174.
  83. Nobel TB, Sihag S, Xing XX, Eljalby M, Hsu M, Tan KS, Sewell DB, Bains MS, Janjigian YY, Wu A, Ku G, Jones DR, Molena D. Oligometastases After Curative Esophagectomy Are Not One-Size-Fits-All. Ann Thorac Surg. 2021 Mar 6;112(6):1775-1781 doi: 10.1016/j.athoracsur.2021.03.002. PMID: 33689743.
  84. Lei M, Siemers NO, Pandya D, Chang H, Sanchez TK, Harbison CT, Szabo PM, Janjigian YY, Ott PA, Sharma P, Bendell JC, Jeffry Evans TR, de Braud F, Chau I, Boyd Z. Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab{plus minus}Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer. Clin Cancer Res. 2021 Mar 29;27(14):392603925. doi: 10.1158/1078-0432.CCR-20-2790. PMID: 33782030.
  85. Sihag S, Nussenzweig SC, Walch H, Hsu M, Tan KS, Sanchez-Vega F, Chatila WK, De La Torre SA, Patel A, Janjigian YY, Maron SB, Ku GY, Tang LH, Hechtman JF, Shah PM, Wu AJ, Jones DR, Molena D, Solit DB, Schultz N, Berger MF. Next-Generation Sequencing of 487 Esophageal Adenocarcinomas Reveals Independently Prognostic Genomic Driver Alterations and Pathways. Clin Cancer Res. 2021 Apr 1; 27(12):3491-3498.lincanres.4707.2020. doi: 10.1158/1078-0432.CCR-20-4707. PMID: 33795256.
  86. Nakauchi M, Vos EL, Tang LH, Gonen M, Janjigian YY, Ku GY, Ilson DH, Maron SB, Yoon SS, Brennan MF, Coit DG, Strong VE. Association of Obesity with Worse Operative and Oncologic Outcomes for Patients Undergoing Gastric Cancer Resection. Ann Surg Oncol. 2021 Apr 8;28(12):7040-7050. doi: 10.1245/s10434-021-09880-5. PMID: 33830355.
  87. Tabernero J, Bang YJ, Van Cutsem E, Fuchs CS, Janjigian YY, Bhagia P, Li K, Adelberg D, Qin SK. KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma. Future Oncol. 2021 May 12;17(22):2847-2855. doi: 10.2217/fon-2021-0176. PMID: 33975465.
  88. Karyn A. Goodman, Fang-Shu Ou, Nathan C. Hall, Tanios Bekaii-Saab, Briant Fruth, Erin Twohy, Michael O. Meyers, Daniel J. Boffa, Kisha Mitchell, Wendy L. Frankel, Donna Niedzwiecki, Anne Noonan, Janjigian YY, Paul J. Thurmes, Alan P. Venook, Jeffrey A. Meyerhardt, Eileen M. O’Reilly, and David H. Ilson, Randomized Phase II Study of PET Response–Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial. Journal of Clinical Oncology. 2021 June 2;39(25):2803-2815. doi: 10.1200/JCO.20.03611. PMID: 34077237.
  89. Janjigian YY, Kohei Shitara, Markus Moehler, Marcelo Garrido, Pamela Salman, Lin Shen, Lucjan Wyrwicz, Kensei Yamaguchi, Tomasz Skoczylas, Arinilda Campos Bragagnoli, Tianshu Liu, Michael Schenker, Patricio Yanez, Mustapha Tehfe, Ruben Kowalyszyn, Michalis V Karamouzis, Ricardo Bruges, Thomas Zander, Roberto Pazo-Cid, Erika Hitre, Kynan Feeney, James M Cleary, Valerie Poulart, Dana Cullen, Ming Lei, Hong Xiao, Kaoru Kondo, Mingshun Li, Jaffer A Ajani, First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. The Lancet. 2021 June 5;398(10294). doi: 10.1016/S0140-6736(21)00988-0.
  90. Ku GY, Kemel Y, Maron SB, Chou JF, Ravichandran V, Shameer Z, Maio A, Won ES, Kelsen D, Strong E, Molena D, Sihag S, Jones DR, Coit DG, Tuvy Y, Cowie K, Solit DB, Schultz N, Hechtman JF, Offit K, Joseph V, Mandelker D, Janjigian YY (co-senior author), Stadler ZK. Prevalence of Germline Alterations on Targeted Tumor-Normal Sequencing of Esophagogastric Cancer. JAMA Netw Open. 2021 July 12. ;4(7):e2114753. doi:10.1001/jamanetworkopen.2021.14753
  91. Moy RH, Sabwa S, Maron SB, Shcherba M, Apollo A, Janjigian YY, Ku GY, Tew WP, Wu AJ, Jones DR, Molena D, Ilson DH, Won E. A nutritional management algorithm in older patients with locally advanced esophageal cancer. J Geriatr Oncol. 2021 Aug 12:S1879-4068(21)00160-0. doi: 10.1016/j.jgo.2021.06.012.
  92. Carr RA, Hsu M, Harrington CA, Tan KS, Bains MS, Bott MJ, Ilson DH, Isbell JM, Janjigian YY, Maron SB, Park BJ, Rusch VW, Sihag S, Wu AJ, Jones DR, Ku GY, Molena D. Induction FOLFOX and PET-Directed Chemoradiation For Locally Advanced Esophageal Adenocarcinoma. Ann Surg. 2021 Aug 13;10.1097/SLA.0000000000005163. PMID: 34387205
  93. E L Vos, R A Carr, M Hsu, M Nakauchi, T Nobel, A Russo, A Barbetta, K S Tan, L Tang, D Ilson, G Y Ku, A J Wu, Janjigian YY, S S Yoon, M S Bains, D R Jones, D Coit, D Molena, V E Strong, Prognosis after neoadjuvant chemoradiation or chemotherapy for locally advanced gastro-oesophageal junctional adenocarcinoma. British Journal of Surgery. 2021 Sept 3;, znab228, https://doi.org/10.1093/bjs/znab228.
  94. Nakauchi M, Vos EL, Carr RA, Barbetta A, Tang LH, Gonen M, Russo A, Janjigian YY, Yoon SS, Sihag S, Rusch VW, Bains MS, Jones DR, Coit DG, Molena D, Strong VE. Distinct Differences in Gastroesophageal Junction and Gastric Adenocarcinoma in 2194 Patients: In Memory of Rebecca A. Carr, February 24, 1988-January 19, 2021. Ann Surg. 2021 Nov 29. 10.1097 doi: 10.1097/SLA.0000000000005320.
  95. Janjigian YY, Kawazoe A, Yañez P, Li N, Lonardi S, Kolesnik O, Barajas O, Bai Y, Shen L, Tang Y, Wyrwicz LS, Xu J, Shitara K, Qin S, Van Cutsem E, Tabernero J, Li L, Shah S, Bhagia P, Chung HC. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature. 2021 Dec 15;600(7890):727-730. PMID: 34912120
  96. Moy, R.H., Greally, M., Chou, J.F., Li, J., Desai, A.M., Chalasani, S.B., Won, E., Kelsen, D.P., Ilson, D.H., Janjigian YY, Capanu, M., Ku, G.Y. Phase I/Ib study of crenolanib with ramucirumab and paclitaxel as second-line therapy for advanced esophagogastric adenocarcinoma. Cancer Chemother Pharmacol. 2022 Jan 23;89(2):255-265. https://doi.org/10.1007/s00280-021-04384-1.
  97. Nguyen B, Fong C, Luthra A, Smith SA, DiNatale RG, Nandakumar S, Walch H, Chatila WK, Madupuri R, Kundra R, Bielski CM, Mastrogiacomo B, Donoghue MTA, Boire A, Chandarlapaty S, Ganesh K, Harding JJ, Iacobuzio-Donahue CA, Razavi P, Reznik E, Rudin CM, Zamarin D, Abida W, Abou-Alfa GK, Aghajanian C, Cercek A, Chi P, Feldman D, Ho AL, Iyer G, Janjigian YY, Morris M, Motzer RJ, O’Reilly EM, Postow MA, Raj NP, Riely GJ, Robson ME, Rosenberg JE, Safonov A, Shoushtari AN, Tap W, Teo MY, Varghese AM, Voss M, Yaeger R, Zauderer MG, Abu-Rustum N, Garcia-Aguilar J, Bochner B, Hakimi A, Jarnagin WR, Jones DR, Molena D, Morris L, Rios-Doria E, Russo P, Singer S, Strong VE, Chakravarty D, Ellenson LH, Gopalan A, Reis-Filho JS, Weigelt B, Ladanyi M, Gonen M, Shah SP, Massague J, Gao J, Zehir A, Berger MF, Solit DB, Bakhoum SF, Sanchez-Vega F, Schultz N. Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. Cell. 2022 Feb 3;185(3):563-575.e11. doi: 10.1016/j.cell.2022.01.003.
  98. Moy RH, Walch HS, Mattar M, Chatila WK, Molena D, Strong VE, Tang LH, Maron SB, Coit DG, Jones DR, Hechtman JF, Solit DB, Schultz N, de Stanchina E, Janjigian YY. Defining and Targeting Esophagogastric Cancer Genomic Subsets with Patient-Derived Xenografts. JCO Precis Oncol. 2022 Feb;6:e2100242. doi:10.1200/PO.21.00242.
  99. Shitara, K., Markus Moehler, Marcelo Garrido, Pamela Salman, Lin Shen, Lucjan Wyrwicz, Kensei Yamaguchi, Tomasz Skoczylas, Arinilda Campos Bragagnoli, Tianshu Liu, Michael Schenker, Patricio Yanez, Mustapha Tehfe, Ruben Kowalyszyn, Michalis V Karamouzis, Ricardo Bruges, Thomas Zander, Roberto Pazo-Cid, Erika Hitre, Kynan Feeney, James M Cleary, Valerie Poulart, Dana Cullen, Ming Lei, Hong Xiao, Kaoru Kondo, Mingshun Li, Jaffer A Ajani, Janjigian YY. Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer. Nature. 2022 Mar;603(7903):942-948. doi: 10.1038/s41586-022-04508-4.
  100. Pereira PMR, Mandleywala K, Monette S, Lumish M, Tully KM, Panikar SS, Cornejo M, Mauguen A, Ragupathi A, Keltee NC, Mattar M, Janjigian YY, Lewis JS. Caveolin-1 temporal modulation enhances antibody drug efficacy in heterogeneous gastric cancer. Nat Commun. 2022 May 9;13(1):2526. doi: 10.1038/s41467-022-30142-9. PMID: 35534471.
  101. Maron SB, Moya S, Morano F, Emmett MJ, Chou JF, Sabwa S, Walch H, Peterson B, Schrock AB, Zhang L, Janjigian YY, Chalasani S, Ku GY, Disel U, Enzinger P, Uboha N, Kato S, Yoshino T, Shitara K, Nakamura Y, Saeed A, Kasi PM, Chao J, Lee J, Capanu M, Wainberg Z, Petty R, Pietrantonio F, Klempner SJ, Catenacci DVT. Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor-Amplified Gastroesophageal Cancer: Retrospective Global Experience. J Clin Oncol. 2022 Aug 1;40(22):2458-2467. doi: 10.1200/JCO.21.02453.
  102. Sihag S, Nussenzweig SC, Walch HS, Hsu M, Tan KS, De La Torre S, Janjigian YY, Maron SB, Ku GY, Tang LH, Shah PM, Wu A, Jones DR, Solit DB, Schultz N, Ganesh K, Berger MF, Molena D. The Role of the TP53 Pathway in Predicting Response to Neoadjuvant Therapy in Esophageal Adenocarcinoma. Clin Cancer Res. 2022 Jun 13;28(12):2669-2678. doi: 10.1158/1078-0432.CCR-21-4016.
  103. Janjigian YY, Van Cutsem E, Muro K, Wainberg Z, Al-Batran SE, Hyung WJ, Molena D, Marcovitz M, Ruscica D, Robbins SH, Negro A, Tabernero J. MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer. Future Oncol. 2022 Jun;18(20):2465-2473. doi: 10.2217/fon-2022-0093.
  104. Vos EL, Maron SB, Krell RW, Nakauchi M, Fiasconaro M, Capanu M, Walch HS, Chatila WK, Schultz N, Ilson DH, Janjigian YY, Ku GY, Yoon SS, Coit DG, Vanderbilt CM, Tang LH, Strong VE. Survival of Locally Advanced MSI-high Gastric Cancer Patients Treated with Perioperative Chemotherapy: A Retrospective Cohort Study. Ann Surg. 2022 Jun 29;10/1097/SLA. 0000000000005501.doi: 10.1097/SLA.0000000000005501.
  105. Abate M, Vos E, Gonen M, Janjigian YY, Schattner M, Laszkowska M, Tang L, Maron SB, Coit DG, Vardhana S, Vanderbilt C, Strong VE. A Novel Microbiome Signature in Gastric Cancer: A Two Independent Cohort Retrospective Analysis. Ann Surg. 2022 Jul 13;276(4):605-615. doi: 10.1097/SLA.0000000000005587. Epub ahead of print.
  106. Nakauchi M, Court CM, Tang LH, Gönen M, Janjigian YY, Maron SB, Molena D, Coit DG, Brennan MF, Strong VE. Validation of the Memorial Sloan Kettering Gastric Cancer Post-Resection Survival Nomogram: Does It Stand the Test of Time? J Am Coll Surg. 2022 Aug 1;235(2):294-304. doi: 10.1097/XCS.0000000000000251. Epub 2022 Apr 28.
  107. Tsai C, Nguyen B, Luthra A, Chou JF, Feder L, Tang LH, Strong VE, Molena D, Jones DR, Coit DG, Ilson DH, Ku GY, Cowzer D, Cadley J, Capanu M, Schultz N, Beal K, Moss NS, Janjigian YY, Maron SB. Outcomes and Molecular Features of Brain Metastasis in Gastroesophageal Adenocarcinoma. JAMA Netw Open. 2022 Aug 1;5(8):e2228083. doi: 10.1001/jamanetworkopen.2022.28083.
  108. R. Rouf, G. Ku, D. Cowzer, C. Harrington, S. Maron, Janjigian YY, D.H. Ilson, D. Molena, S. Sihag, C. Hajj, C.H. Crane, A.J. Wu. FOLFOX-Based Chemoradiation as Non-Operative Management for Esophageal Adenocarcinoma. International Journal of Radiation Oncology*Biology*Physics. 2022 Nov 1;114(3). doi: 10.1016/j.ijrobp.2022.07.1046.
  110. Murciano-Goroff, Y.R., Schram, A.M., Rosen, E.Y., Won, H, Gong, Y., Marie Noronha, A., Janjigian YY, Stadler, Z.K., Chang, J.C., Yang, Soo-Ryum, Mandelker, D., Offit, K., Berger, M.F., Donoghue, M.T.A., Bandlamudi, C., Drilon, A. Reversion mutations in germline BRCA1/2-mutant tumors reveal a BRCA-mediated phenotype in non-canonical histologies. Nat Commun 13. 2022 Nov; 23. 13(1):7182 https://doi.org/10.1038/s41467-022-34109-8.
  111. Cowzer D, Wu AJ, Sihag S, Walch HS, Park BJ, Jones DR, Gu P, Maron SB, Sugarman R, Chalasani SB, Shcherba M, Capanu M, Chou JF, Choe JK, Nosov A, Adusumilli PS, Yeh R, Tang LH, Ilson DH, Janjigian YY, Molena D, Ku GY. Durvalumab and pet-directed chemoradiation in locally advanced esophageal adenocarcinoma – a phase ib/ii study. Ann Surg. 2023 Feb 10. doi: 10.1097/SLA.0000000000005818. Online ahead of print. PMID: 36762546
  112. Maron SB, Walid C, Walch H, Chou JF, Ceglia N, Ptashkin R, Do RKG, Paroder V, Pandit-Taskar N, Lewis JS, De Castria TB, Sabwa S, Socolow F, Feder L, Thomas J, Schulze I, Kim K, Elzein A, Bojilova V, Zatzman M, Bhanot U, Nagy RJ, Lee J, Simmons M, Segal M, Ku GY, Ilson DH, Capanu M, Hectman JF, Merghoub T, Shah S, Schultz N, Soliy DB, Janjigian YY. Determinants of surivial in HER2+ metastatic esophagogastric cancer. Clincal Cancer Res. 2023 July 5. doi: 10.1158/1078-04322. CCR-22-3769.
  113. Boerner T, Carr R, Hsu M, Tan KS, Sigel C, Tang L, Harrington C, Ku GY, Ilson DH, Janjigian YY, Wu AJ, Sihag S, Bains MS, Bott MJ, Isbell JM, Park BJ, Jones DR, Molena D. Prognostic value of circumferential radial margin involvement in esophagectomy for esophageal cancer: A case series.International Journal of Surgery. 2023 August 7. doi:10.1097/JS9.0000000000000609.
  114. Cytryn SL, Moy RH, Cowzer D, Shah RH, Chou JF, Joshi SS, Ku GY, Maron SB, Desai A, Yang J, Sugarman R, Rao D, Goldberg Z, Charalambous C, Lapshina M, Antoine A, Socolow F, Trivedi N, Capanu M, Gerdes H, Schattner MA, Simmons M, Lacouture ME, Paroder V, Tang LH, Shia J, Ilson DH, Solit DB, Berger MF, Janjigian YY. First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trial. Lancet Oncol. 2023 September 1. https://doi.org/10.1016/S1470-2045(23)00358-3.
  115. Moehler M, Xiao H, Blum SI, Elimova E, Cella D, Shitara K, Ajani JA, Janjigian YY, Garrido M, Shen L, Yamaguchi K, Liu T, Schenker M, Kowalyszyn R, Bragagnoli AC, Bruges R, Montesarchio V, Pazo-Cid R, Hunter S, Davenport E, Wang J, Kondo K, Li M, Wyrwicz. Health-related quality of life with nivolumab plus chemotherapy versus chemotherapy in patients with advanced gastric/gastroesophageal junction cancer or esophageal adenocarcinoma from CheckMate 649. J Clin Oncol. 2023 September 15. https://doi.org/10.1200/JCO.23.00170.
  116. Harrold EC, Foote MB, Rousseau B, Walch H, Kemel Y, Richards AL, Keane F, Cercek A, Yaeger R, Rathkopf D, Segal NH, Patel Z, Maio A, Borio M, O’Reilly EM, Reidy D, Desai A, Janjigian YY, Murciano-Goroff YR, Carlo MI, Latham A, Liu YL, Walsh MF, Ilson D, Rosenberg JE, Markowitz AJ, Weiser MR, Rossi AM, Vanderbilt C, Mandelker D, Bandlamudi C, Offit K, Berger MF, Solit DB, Saltz L, Shia J, Diaz LA, Stadler ZK. Neoplasia risk in patients with Lynch syndrome treated with immune checkpoint blockade. Nat Med 29, 2458-2463. 2023 October 16. https://doi.org/10.1038/s41591-023-02544-9.
  117. Janjigian YY, Kawazoe A, Bai Y, Xu J, Lonardi S, Metges JP, Yanez P, Wyrwicz LS, Shen L, Ostapenko Y, Bilici M, Chung HC, Shitara K, Qin SK, Van Cutsem E, Tabernero J, Li K, Shih CS, Bhagia P, Rha SY. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma:interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. The Lancet. 2023 October 20.  https://doi.org/10.1016/S0140-6736(23)02033-0.
  118. Magahis PT, Maron SB, Cowzer D, King S, Schattner M, Janjigian YY, Faleck, Laszkowska M. Impact of Helicaobacter pylori infection status on outcomes among patients with advanced gastric cancer treated with immune checkpoint inhibitors. J Immunother Cancer. 2023 October 11 (1):e007699. doi: 10.1136/jitc-2023-007699.
  119. Shitara K, Rha SY, Wyrwicz LS, Oshima T, Karaseva N, Osipov M, Yasui H, Yabusakui H, Afanasyev S, Park YK, Al-Batran SE, Yoshikawa T, Yanez, P, Di Bartolomeo M, Lonardi S, Tabernero J, Van Cutsem E, Janjigian YY, Oh DY, Xu J, Fang X, Shih CS, Bhagia P, Bang YJ. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomized phase 3 study. The Lancet. 2023 December 19. https://doi.org/10.1016/S1470-2045(23)00541-7.
  120. Fick CN, Dunne EG, Sihag S, Molena D, Cytryn SL, Janjigian YY, Wu AJ, Worrell SG, Hofstetter WL, Jones DR, Gray KD. Immunotherapy for Resectable Locally Advanced Esophageal Carcinoma. The Annals of Thoracic Surgery. 2024 February 5. https://doi.org/10.1007/s10120-023-01457-3.
  121. Janjigian YY, Ajani JA, Moehler M, Shen L, Garrido M, Gallardo C, Wyrwicz, Yamaguchi K, Cleary JM, Elimova E, Karamouzis M, Bruges R, Skoczylas T, Bragagnoli, Liu T, Tehfe M, Zander T, Kowalyszyn R, Pazo-Cid R, Schenker M, Feeny K, Wang R, Lei M, Chen C, Nathani R, Shitara K. First-line nivolumab plus chemotherapy for advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: 3-year follow-up of the phase III CheckMate 649 trial. J Clin Oncol. 2024 February 21. https://doi.org/10.1200/JCO.23.01601
  122. Kitagawa Y, Matsuda S, Gotoda T, Kato K, Wijnhoven B, Lordick F, Bhandari P, Kawakubo H, Kodera Y, Terashima M, Muro K, Takeuchi H, Mansfield PF, Kurokawa Y, So J, Monig SP, Shitara K, Rha SY, Janjigian Y, Takahari D, Chau I, Sharma P, Li J, De Manzoni G, Nilsson M, Kassab P, Hofstetter WL, Smyth EC, Lorenzen S, Doki Y, Law S, Oh DY, Ho KY, Koike T, Shen L, Van Hillegersberg R, Kawakami H, Xu RH, Yahagi N, Lee YY, Singh R, Ryu MH, Ishihara R, Xiao Z, Kusano C, Grabsch HI, Hara H, Mukaisho KI, Makino T, Kanda M, Booka E, Suzuki S, Hatta W, Kato M, Maekawa A, Kawazoe A, Yamamoto S, Nakayama I, Narita Y, Yang HK, Yoshida M, Sano T. Clinical Practice guidelines for esophagogastric junction cancer: Upper GI Oncology Summit 2023. Gastric Cancer. 2024 February 22. https://doi.org/10.1007/s10120-023-01457-3.
  123. Vitiello GA, Jayaprakasam VS, Tang LH, Schattner MA, Janjigian YY, Ku GY, Maron SB, Schoder H, Larson SM, Gonen M, Datta J, Coit DG, Brennan M, Strong VE. Patient metabolic profile defined by liver and muscle 18 F‑FDG PET avidity is independently associated with overall survival in gastric cancer. Gastric Cancer. 2024 March 4. https://doi.org/10.1007/s10120-024-01485-7.
  124.  Cytryn SL, Pandit-Taskar N, Lumish MA, Maron SB, Gu P, Ku GY, Chou JF, Capanu M, Antonie A, Loegel D, Feder L, Philemond S, Lyashchenko SK, Lewis JS, Paroder V, Srivastava A, Tang LH, Schoder H, Janjigian YY. 18F-BMS-986229 PET to Assess Programmed-Death Ligand 1 Status in Gastroesophageal Cancer. Journal of Nuclear Medicine. 2024 March 21. https://doi.org/10.2967/jnumed.123.267186
  125. Gupta A, Michelini F, Shao H, Yeh C, Drago JZ, Liu D, Rosiek E, Romin Y, Ghafourian N, Thyparambil S, Misale S, Park W, de Stanchina E, Janjigian YY, Yaeger R, Li BT, Chandarlapaty S. EGFR-directed antibodies promote HER2 ADC internalization and efficacy. Cell Rep Med. 2024 Oct 11:101792. https://doi.org/10.1016/j.xcrm.2024.101792
  126. Semaan K, Nawfal R, Nally E, Janjigian YY, Robert C, Peters S, Powles T, Choueiri TK. Landscape of subsequent therapies in perioperative immunotherapy trials across multiple cancer types. Lancet Oncol. 2024;25(7):890-901. doi:10.1016/S1470-2045(24)00513-8.
  127. Sewell M, Toumbacaris N, Tan KS, Bahadur N, Philip J, Shah NJ, Niederhausern A, Tavarez Martinez C, Zheng H, Boerner T, Janjigian YY, Maron SB, Bott MJ, Gray KD, Park BJ, Sihag S, Jones DR, Ku GY, Wu AJ, Molena D. Esophagectomy may have a role in stage IV esophageal adenocarcinoma. J Thorac Cardiovasc Surg. 2024 Nov 22:S0022-5223(24)01087-0. doi: 10.1016/j.jtcvs.2024.11.015.
  128. Magahis PT, Cornet N, Tang L, Arora K, Hingorani N, King S, Markowitz AJ, Schattner M, Shimada S, Maron SB, Vardhana S, Lumish M, Cercek A, Janjigian YY, Coit D, Mendelsohn RB, Berger MF, Strong VE, Stadler ZK, Laszkowska M. Differences in Ancestry and Presence of Gastric Precursor Lesions in Individuals With Young- and Average-Onset Gastric Cancer. Cancer Med. 2024 Dec;13(23):e70451. doi: 10.1002/cam4.70451. PMID: 39629931; PMCID: PMC11615756.
  129. Abate M, Stroobant EE, Fei T, Lin YH, Shimada S, Drebin H, Chen E, Tang LH, Shah SP, Wolchok JD, Janjigian YY, Strong VE, Vardhana SA. Host Tissue Factors Predict Immune Surveillance and Therapeutic Outcomes in Gastric Cancer. Cancer Immunol Res. 2025 Apr 2;13(4):591-601. doi: 10.1158/2326-6066.CIR-23-0563. PMID: 39786344; PMCID: PMC11964842.
  130. White C, Jayaprakasam VS, Tenet M, Tang LH, Schattner MA, Janjigian YY, Maron SB, Schöder H, Larson SM, Gönen M, Datta J, Coit DG, Mauguen A, Strong VE, Vitiello GA. PET-CT-based host metabolic (PETMet) features are associated with pathologic response in gastroesophageal adenocarcinoma. Eur J Surg Oncol. 2025 Jan 8;51(5):109589. doi: 10.1016/j.ejso.2025.109589. Epub ahead of print. PMID: 39808889.
  131. Shitara K, Janjigian YY, Ajani J, Moehler M, Yao J, Wang X, Chhibber A, Pandya D, Shen L, Garrido M, Gallardo C, Wyrwicz L, Yamaguchi K, Skoczylas T, Bragagnoli A, Liu T, Schenker M, Yañez P, Kowalyszyn R, Karamouzis M, Zander T, Feeney K, Elimova E, Doshi P, Li M, Lei M. Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial. Nat Med. 2025 Mar 7. doi: 10.1038/s41591-025-03575-0. Epub ahead of print. PMID: 40055521.
  132. Janjigian YY, Cecchini M, Shitara K, Enzinger PC, Wainberg ZA, Chau I, Satoh T, Lee J, Nebozhyn M, Loboda A, Kobie J, Vajdi A, Shih CS, Cristescu R, Cao ZA. Genomic Landscape of Late-Stage Gastric Cancer: Analysis From KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Studies. JCO Precis Oncol. 2025 Mar;9:e2400456. doi: 10.1200/PO-24-00456. Epub 2025 Mar 21. Erratum in: JCO Precis Oncol. 2025 Apr;9:e2400266. doi: 10.1200/PO-25-00266. PMID: 40117530; PMCID: PMC11949223.
  133. Janjigian YY, Cecchini M, Shitara K, Enzinger PC, Wainberg ZA, Chau I, Satoh T, Lee J, Nebozhyn M, Loboda A, Kobie J, Vajdi A, Shih CS, Cristescu R, Cao ZA. Erratum: Genomic Landscape of Late-Stage Gastric Cancer: Analysis From KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Studies. JCO Precis Oncol. 2025 Apr;9:e2400266. doi: 10.1200/PO-25-00266. Epub 2025 Apr 23. Erratum for: JCO Precis Oncol. 2025 Mar;9:e2400456. doi: 10.1200/PO-24-00456. PMID: 40267390.
  134. Cercek A, Foote MB, Rousseau B, Smith JJ, Shia J, Sinopoli J, Weiss J, Lumish M, Temple L, Patel M, Wilde C, Saltz LB, Argiles G, Stadler Z, Artz O, Maron S, Ku G, Gu P, Janjigian YY, Molena D, Iyer G, Coleman J, Abida W, Cohen S, Soares K, Schattner M, Strong VE, Yaeger R, Paty P, Shcherba M, Sugarman R, Romesser PB, Zervoudakis A, Desai A, Segal NH, El Dika I, Widmar M, Wei I, Pappou E, Fumo G, Aparo S, Gonen M, Gollub M, Jayaprakasham VS, Kim TH, Garcia Aguilar J, Weiser M, Diaz LA Jr. Nonoperative Management of Mismatch Repair-Deficient Tumors. N Engl J Med. 2025 Apr 27. doi: 10.1056/NEJMoa2404512. Epub ahead of print. PMID: 40293177.
  135. Walch HS, Borpatragohain R, Jee J, Chatila W, Fong C, Maron SB, Ku GY, Ilson DH, Janjigian YY, Wu AJ, Shah P, Coit DG, Bains MS, Rusch VW, Park BJ, Bott MJ, Gray K, Jones DR, Berger M, Schultz N, Strong VE, Molena D, Sihag S. Clinical Implications of The Cancer Genome Atlas Molecular Classification System in Esophagogastric Cancer. Clin Cancer Res. 2025 Apr 29:OF1-OF10. doi: 10.1158/1078-0432.CCR-24-3473. Epub ahead of print. PMID: 40299774.
  136. Sundar R, Nakayama I, Markar SR, Shitara K, van Laarhoven HWM, Janjigian YY, Smyth EC. Gastric cancer. Lancet. 2025 May 1:S0140-6736(25)00052-2. doi: 10.1016/S0140-6736(25)00052-2. Epub ahead of print. PMID: 40319897.

Reviews and Editorials

  1. Janjigian YY, Nimer S: A role for Wnt signaling in adult T-cell leukaemia Leuk Res 29:475-6, 2005.
  2. Janjigian YY, Miller VA.: Do molecular diagnostics add to clinical characteristics in selecting patients for gefitinib treatment? Nat Clin Pract Oncol. 2008 Jan;5(1):10-1
  3. Janjigian YY. Lapatinib in gastric cancer: What is the LOGiCal next step? J Clin Oncol. 2016 February 10. PMID: 26700116
  4. Elimova E, Janjigian YY, Mulcahy M, Catenacci DV, Blum MA, Almhanna K, Hecht JR, Ajani JA.It Is Time to Stop Using Epirubicin to Treat Any Patient With Gastroesophageal Adenocarcinoma. J Clin Oncol. 2017 Feb. PMID: 28129519
  5. Mondaca S, Yoon SS, Strong VE, Ilson DH, Greally M, Janjigian YY. Microsatellite Instability as a Predictive Biomarker for Adjuvant Chemotherapy in Gastric Cancer: Are we there yet? Ann Surg. 2018 November 22. PMID: 30480560
  6. Mondaca S, Janjigian YY. Cancer. 2019 Apr 15;125(8):1214-1217. doi: 10.1002/cncr.31940. Epub 2019 Jan 22. No abstract available. PMID: 30668898
  7. M. Lumish, N. Tarazona, Janjigian YY. Postoperative ctDNA monitoring: a canary in a coalmine. Annals of Oncology. 2021 January 5. ISSN 0923-7534
  8. Janjigian YY, Wolchok JD, Ariyan CE. Eradicating micrometastases with immune checkpoint blockade: Strike while the iron is hot. Cancer Cell. 2021 Jun 14;39(6):738-742. doi: 10.1016/j.ccell.2021.05.013. PMID: 34129818.
  9. Reynolds JV, Cowzer D, Janjigian YY. Should chemoradiotherapy be standard to maximise cure in localised gastro-oesophageal cancer? Lancet Oncol. 2022 Jul;23(7):847-849. doi: 10.1016/S1470-2045(21)00753-1. PMID: 35772454.
  10. Lumish, M., Maron, S., Paroder, V., Chou, J., Capanu, M., Philemond, S., O’Donoghue, J., Schoder, H., Lewis, J., Lyaschenko, S., Pandit-Taskar, N., Janjigian YY. Noninvasive assessment of human epidermal growth factor receptor 2 (HER2) in esophagogastric cancer using Zr-trastuzumab PET: a pilot study. Journal of Nuclear Medicine. 2022 November. doi: 10.2967/jnumed.122.264470

Book Chapters

  1. Kumar N, Janjigian YY, Schwartz DR. Paradoxical worsening of shock after the use of a percutaneous mechanical thrombectomy device in a postpartum patient with a massive pulmonary embolism. Chest 2007 Aug;132(2):677-9.
  2. Janjigian YY and Shah MA: Molecularly targeted therapies in advanced gastric cancer. Minerva Gastroenterol e Dietologica. 2011 Mar; 57(1):75-88.
  3. Janjigian YY and Bains, MS: Perioperative Therapy for Localized Esophageal Cancer. Book Chapter in ECAB Clinical Update: surgical Gastroenterology and Liver Transplantation, Elsevier 2011. (Book chapter)
  4. Ang C, Janjigian YY, Shamseddine A, Tawil A, Lowery MA, Intlekofer A, Faraj W, Al-Olayan A, Tang L, O’Reilly EM, Geara F, Al-Kutoubi A, Kelsen DP, Abou-Alfa GK.A case of advanced gastric cancer. Gastrointest Cancer Res. 2012 Mar; 5(2):59-63. PMID: 22690259
  5. Janjigian YY and Kelsen DP; Genomic Dysregulation in Gastric Tumors. J Surg Oncol. 2013 Mar;107(3):237-42 PMID: 23042588
  6. Janjigian YY. Gastric Cancer, Pocket Oncology. 2014.
  7. Jhaveri K, Ochiana SO, Dunphy MP, Gerecitano JF, Corben AD, Peter RI, Janjigian YY, Gomes-Dagama EM, Koren J 3rd, Modi S, Chiosis G. Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions. Expert Opin Investig Drugs. 2014 Mar 26. PMID: 24669860
  8. Janjigian YY. Role of HER2 in Gastric Cancers, Gastric Cancer: Principles and Practice. 2015. (Book chapter)
  9. Won E, Janjigian YY, Ilson DH. HER2 directed therapy for gastric/esophageal cancers. J Gastrointest Oncol. 2016 Aug;7(4):506-14. PMID: 24811128
  10. Aguiar PN Jr, Muniz TP, Miranda RR, Tadokoro H, Forones NM, Monteiro ID, Castelo-Branco P Janjigian YY, de Mello RA. Current advances in target therapies for metastatic gastric cancer: improving patient care. Future Oncol. 2016 Mar;12(6):839-54. PMID: 26838766.
  11. Kelly CM, Janjigian YY. The genomics and therapeutics of HER2-positive gastric cancer-from trastuzumab and beyond. J Gastrointest Oncol. 2016 Oct 7. PMID: 27747089
  12. Lordick F, Janjigian YY. Clinical impact of tumour biology in the management of gastroesophageal cancer. Nat Rev Clin Oncol. 2016 Jun;13(6):348-60. PMID: 26925958
  13. Lordick F, Shitara K, Janjigian YY. New Agents on the Horizon in Gastric Cancer. Ann Oncol. 2017 Aug 1;28(8):1767-1775. PMID: 28184417
  14. Janjigian YY, Braghiroli MI. Current Progress in Human Epidermal Growth Factor Receptor2 Targeted Therapies in Esophagogastric Cancer. Surg Oncol Clin N Am. 2017 Apr;26(2):313-324.PMID: 28279471
  15. Ajani JA, Lee J, Sano T, Janjigian YY, Fan D, Song S. Gastric adenocarcinoma. Nat Rev Dis Primers. 2017 Jun 1;3:17036 PMID: 28569272
  16. Janjigian YY, Bissig M, Curigliano G, Coppola J, Latymer M. Talking to patients about biosimilars. Future Oncol. 2018 Jun 1. PMID: 29856243
  17. Cohen NA, Strong VE, Janjigian YY.  Checkpoint blockage in Esophagogastric Cancer. J Surg Oncol. 2018 Jun 7. Review. PMID: 29878357
  18. De Mello RA, Lordick F, Muro K, Janjigian YY. Current and Future Aspects of Immunotherapy for Esophageal and Gastric Malignancies. Am Soc Clin Oncol Educ Book. 2019 Jan. Review. PMID: 31099644
  19. Nagavarakishore Pillarsetty,Komal Jhaveri ,Tony Taldone Eloisi Caldas-Lopes , Blesida Punzalan , Suhasini Joshi , Alexander Bolaender Mohammad M. Uddin , Anna Rodina , Pengrong Yan , Anson Ku , Thomas Ku , Smit K. Shah , Serge Lyashchenko , Eva Burnazi , Tai Wang , Nicolas LeCompte , Janjigian YY , Anas Younes, Connie W. Batlevi, Monica L. Guzman, Gail J. Roboz , Jacek Koziorowski, Pat Zanzonico , Mary L. Alpaugh ,Adriana Corben, Shanu Modi , Larry Norton , Steven M. Larson ,Jason S. Lewis, Gabriela Chiosis , John F. Gerecitano , Mark P.S. Dunphy: Paradigms for Precision Medicine in Epichaperome Cancer Therapy. 2019
  20. Paradigms for Precision Medicine in Epichaperome Cancer Therapy. Pillarsetty N, Jhaveri K, Taldone T, Caldas-Lopes E, Punzalan B, Joshi S, Bolaender A, Uddin MM, Rodina A, Yan P, Ku A, Ku T, Shah SK, Lyashchenko S, Burnazi E, Wang T, Lecomte N, , Janjigian YY, Younes A, Batlevi CW, Guzman ML, Roboz GJ, Koziorowski J, Zanzonico P, Alpaugh ML, Corben A, Modi S, Norton L, Larson SM, Lewis JS, Chiosis G, Gerecitano JF, Dunphy MPS.Cancer Cell. 2019 Oct 21. pii: S1535-6108(19)30427-1. doi: 10.1016/j.ccell.2019.09.007. PMID: 31668946
  21. Nakamura, Y., Kawazoe, A., Lordick, F., Janjigian YY, Shitara, K. Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm. Nat Rev Clin Oncol (2021).
  22. Moy R.H., Janjigian Y.Y. (2021) Stomach: The Standard of Care ± HER2. Cancer Immunotherapy. Springer, Cham. https://doi.org/10.1007/13905_2021_4
  23. Guercio BJ, Iyer G, Kidwai WZ, Lacouture ME, Ghafoor S, Rossi AM, Assis DN, Chen YB, Busam KJ, Janjigian YY, Jhaveri K, Feldman DR, Capozzi A, Figueroa V, Bajorin DF, Rosenberg JE, Hollmann TJ, Funt SA. Treatment of Metastatic Extramammary Paget Disease with Combination Ipilimumab and Nivolumab: A Case Report. Case Rep Oncol. 2021 Mar 12;14(1):430-438. doi: 10.1159/000514345. PMID: 33790764.
  24. Nakamura Y, Kawazoe A, Lordick F, Janjigian YY, Shitara K. Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm. Nat Rev Clin Oncol. 2021 Mar 31. doi: 10.1038/s41571-021-00492-2. PMID: 33790428.
  25. de Castria TB, Tang L, Queiroz MM, Awni BM, Paroder V, Shamseddine A, Bariani GM, Mukherji D, Matar CF, Fernandes GDS, El-Olayan A, Sabatin F, Elias R, Gupta R, Janjigian YY, Abou-Alfa GK. Hepatoid esophagogastric adenocarcinoma and tumoral heterogeneity: a case report. J Gastrointest Oncol 2021 Sept 30. doi: 10.21037/jgo-21-287.
  26. Cowzer D, Janjigian YY. Top advances in esophageal/gastroesophageal junction cancers in 2021. Cancer. 2022 Feb 18. doi: 10.1002/cncr.34140. Epub ahead of print. PMID: 35179774.
  27. Yang J, Janjigian YY. Immune checkpoint blockade and targeted therapies in esophageal cancer. Thoracic Surgery Clinics. 2022 July 2. doi: 10.1016/j.thorsurg.2022.07.002.

Oncologist Near Me – Yelena Janjigian: A Global Leader in Gastrointestinal Oncology

  • Office address: 300 E66th Street, BAIC 1001, New York, NY 10065
  • Office telephone:  +1-646-888-4286
  • Work email: [email protected]